Abstract
Aim:
To estimate the budget impact (BI) of introducing aripiprazole once-monthly 400 mg/300 mg (AOM 400) in the maintenance monotherapy treatment of bipolar I disorder versus long-acting injectables, oral antipsychotics and best supportive care.
Methods:
A BI model was developed from a US-payer perspective using treatment-related, hospitalization and adverse event management cost estimates for a hypothetical 1,000,000-member health plan over a 5-year period.
Results:
Market share of AOM 400 was predicted to increase from 0.6% in Year 1 (current scenario) to 1.3% in Year 5 (predicted scenario), with predicted increases for paliperidone palmitate, asenapine and cariprazine. Treatment-related costs explained the BI increase, while adverse event and hospitalization costs were reduced. The per member per month incremental cost ranged from US$0.06 to US$0.26 in Years 1-5. The largest increases were predicted for paliperidone palmitate.
Conclusion:
As market shares of atypical antipsychotics are predicted to increase, payers may wish to re-evaluate their use.
Keywords:
antipsychotic; aripiprazole; bipolar I disorder; budget impact; long-acting injectable.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antipsychotic Agents / administration & dosage
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / economics*
-
Aripiprazole / administration & dosage
-
Aripiprazole / adverse effects
-
Aripiprazole / economics*
-
Bipolar Disorder / drug therapy
-
Bipolar Disorder / economics*
-
Budgets
-
Cost-Benefit Analysis
-
Delayed-Action Preparations
-
Dibenzocycloheptenes
-
Drug Administration Schedule
-
Drug Costs
-
Health Care Costs
-
Heterocyclic Compounds, 4 or More Rings / administration & dosage
-
Heterocyclic Compounds, 4 or More Rings / adverse effects
-
Heterocyclic Compounds, 4 or More Rings / economics
-
Hospitalization
-
Humans
-
Injections, Intramuscular
-
Injections, Subcutaneous
-
Medication Adherence
-
Paliperidone Palmitate / administration & dosage
-
Paliperidone Palmitate / adverse effects
-
Paliperidone Palmitate / economics
-
Piperazines / administration & dosage
-
Piperazines / adverse effects
-
Piperazines / economics
-
Schizophrenia / drug therapy
-
Schizophrenia / economics
Substances
-
Antipsychotic Agents
-
Delayed-Action Preparations
-
Dibenzocycloheptenes
-
Heterocyclic Compounds, 4 or More Rings
-
Piperazines
-
Aripiprazole
-
cariprazine
-
asenapine
-
Paliperidone Palmitate